Groowe Groowe / Newsroom / AKBA
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

AKBA News

Akebia Therapeutics, Inc.

Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights

globenewswire.com
AKBA

U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week

globenewswire.com
AKBA

Form 8-K

sec.gov
AKBA

Form 8-K

sec.gov
AKBA

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

globenewswire.com
AKBA

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

globenewswire.com
AKBA

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com
AKBA

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

globenewswire.com
AKBA

Focal Segmental Glomerulosclerosis (FSGS) Market Insights, Epidemiology and Forecast 2026-2036 - Targeted Therapies Reshape Treatment Through 2036

globenewswire.com
TARA AMTX AKBA APLS NVS

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com
AKBA